A Randomized, Multicenter Phase 3 Study Comparing 2% Rebamipide (OPC-12759) with 0.1% Sodium Hyaluronate in the Treatment of Dry Eye

      Objective

      To investigate the efficacy of 2% rebamipide ophthalmic suspension compared with 0.1% sodium hyaluronate ophthalmic solution for the treatment of patients with dry eye.

      Design

      Randomized, multicenter, active-controlled parallel-group study.

      Participants

      One hundred eighty-eight patients with dry eye.

      Methods

      Following a 2-week screening period, patients were allocated randomly to receive 2% rebamipide or 0.1% sodium hyaluronate, administered as 1 drop in each eye 4 or 6 times daily, respectively, for 4 weeks.

      Main Outcome Measures

      There were 2 primary end points: changes in the fluorescein corneal staining (FCS) score to determine noninferiority of 2% rebamipide and changes in the lissamine green conjunctival staining (LGCS) score to determine superiority. Secondary objective end points were Schirmer's test results and tear film breakup time (TBUT). Secondary subjective end points were dry eye–related ocular symptoms (foreign body sensation, dryness, photophobia, eye pain, and blurred vision) score and the patients' overall treatment impression score.

      Results

      In the primary analysis, the mean change from baseline in FCS scores verified noninferiority, indicated significant improvement, and, in LGCS scores, verified the superiority of 2% rebamipide to 0.1% sodium hyaluronate. Values for the Schirmer's test and TBUT were comparable between the 2 groups. For 2 dry eye–related ocular symptoms—foreign body sensation and eye pain—2% rebamipide showed significant improvements over 0.1% sodium hyaluronate. Patients had a significantly more favorable impression of 2% rebamipide than of 0.1% sodium hyaluronate; 64.5% rated treatment as improved or markedly improved versus 34.7%, respectively. No serious adverse events were observed.

      Conclusions

      Administration of 2% rebamipide was effective in improving both the objective signs and subjective symptoms of dry eye. Those findings, in addition to the well-tolerated profile of 2% rebamipide, clearly show that it is an effective therapeutic method for dry eye.

      Financial Disclosure(s)

      Proprietary or commercial disclosure may be found after the references.

      References

      1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007).
        Ocul Surf. 2007; 5: 75-92
        • de Pinho Tavares F.
        • Fernandes R.S.
        • Bernardes T.F.
        • et al.
        Dry eye disease.
        Semin Ophthalmol. 2010; 25: 84-93
        • Peral A.
        • Dominguez-Godinez C.O.
        • Carracedo G.
        • Pintor J.
        Therapeutic targets in dry eye syndrome.
        Drug News Perspect. 2008; 21: 166-176
        • Gayton J.L.
        Etiology, prevalence, and treatment of dry eye disease.
        Clin Ophthalmol. 2009; 3: 405-412
        • Friedman N.J.
        Impact of dry eye disease and treatment on quality of life.
        Curr Opin Ophthalmol. 2010; 21: 310-316
        • Gipson I.K.
        The ocular surface: the challenge to enable and protect vision: the Friedenwald lecture.
        Invest Ophthalmol Vis Sci. 2007; 48 (4391–8): 4390
        • Shimmura S.
        • Ono M.
        • Shinozaki K.
        • et al.
        Sodium hyaluronate eyedrops in the treatment of dry eyes.
        Br J Ophthalmol. 1995; 79: 1007-1011
        • Aragona P.
        • Di Stefano G.
        • Ferreri F.
        • et al.
        Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjogren's syndrome patients.
        Br J Ophthalmol. 2002; 86: 879-884
        • Condon P.I.
        • McEwen C.G.
        • Wright M.
        • et al.
        Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome.
        Br J Ophthalmol. 1999; 83: 1121-1124
        • American Academy of Ophthalmology Cornea/External Disease Panel
        Preferred Practice Pattern Guidelines. Dry Eye Syndrome. Limited revision.
        American Academy of Ophthalmology, San Francisco, CA2011 (Accessed July 26, 2012)
        • Slusser T.G.
        • Lowther G.E.
        Effects of lacrimal drainage occlusion with nondissolvable intracanalicular plugs on hydrogel contact lens wear.
        Optom Vis Sci. 1998; 75: 330-338
        • Lemp M.A.
        Advances in understanding and managing dry eye disease.
        Am J Ophthalmol. 2008; 146: 350-356
        • Corfield A.P.
        • Carrington S.D.
        • Hicks S.J.
        • et al.
        Ocular mucins: purification, metabolism and functions.
        Prog Retin Eye Res. 1997; 16: 627-656
        • Ralph R.A.
        Conjunctival goblet cell density in normal subjects and in dry eye syndromes.
        Invest Ophthalmol. 1975; 14: 299-302
        • Danjo Y.
        • Watanabe H.
        • Tisdale A.S.
        • et al.
        Alteration of mucin in human conjunctival epithelia in dry eye.
        Invest Ophthalmol Vis Sci. 1998; 39: 2602-2609
        • Argueso P.
        • Balaram M.
        • Spurr-Michaud S.
        • et al.
        Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome.
        Invest Ophthalmol Vis Sci. 2002; 43: 1004-1011
        • Shigemitsu T.
        • Shimizu Y.
        • Ishiguro K.
        Mucin ophthalmic solution treatment of dry eye.
        Adv Exp Med Biol. 2002; 506: 359-362
        • Iijima K.
        • Ichikawa T.
        • Okada S.
        • et al.
        Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test.
        Dig Dis Sci. 2009; 54: 1500-1507
        • Naito Y.
        • Yoshikawa T.
        Rebamipide: a gastrointestinal protective drug with pleiotropic activities.
        Expert Rev Gastroenterol Hepatol. 2010; 4: 261-270
        • Yamasaki K.
        • Kanbe T.
        • Chijiwa T.
        • et al.
        Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat.
        Eur J Pharmacol. 1987; 142: 23-29
        • Urashima H.
        • Okamoto T.
        • Takeji Y.
        • et al.
        Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model.
        Cornea. 2004; 23: 613-619
        • Urashima H.
        • Takeji Y.
        • Okamoto T.
        • et al.
        Rebamipide increases mucin-like substance contents and periodic acid Schiff reagent-positive cells density in normal rabbits.
        J Ocul Pharmacol Ther. 2012; 28: 264-270
        • Takeji Y.
        • Urashima H.
        • Aoki A.
        • Shinohara H.
        Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells.
        J Ocul Pharmacol Ther. 2012; 28: 259-263
        • Kinoshita S.
        • Awamura S.
        • Oshiden K.
        • et al.
        Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
        Ophthalmology. 2012; 119: 2471-2478
        • Pocock S.J.
        • Simon R.
        Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
        Biometrics. 1975; 31: 103-115
        • Lemp M.A.
        Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes.
        CLAO J. 1995; 21: 221-232
        • Schaumberg D.A.
        • Dana R.
        • Buring J.E.
        • Sullivan D.A.
        Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies.
        Arch Ophthalmol. 2009; 127: 763-768
      2. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007).
        Ocul Surf. 2007; 5: 93-107
        • Hamrah P.
        • Alipour F.
        • Jiang S.
        • et al.
        Optimizing evaluation of lissamine green parameters for ocular surface staining.
        Eye (Lond). 2011; 25: 1429-1434
        • Khanal S.
        • Tomlinson A.
        • McFadyen A.
        • et al.
        Dry eye diagnosis.
        Invest Ophthalmol Vis Sci. 2008; 49: 1407-1414
        • Sall K.
        • Stevenson O.D.
        • Mundorf T.K.
        • Reis B.L.
        • CsA Phase 3 Study Group
        Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease.
        Ophthalmology. 2000; 107: 631-639
        • Rivas L.
        • Oroza M.A.
        • Perez-Esteban A.
        • Murube-del-Castillo J.
        Morphological changes in ocular surface in dry eyes and other disorders by impression cytology.
        Graefes Arch Clin Exp Ophthalmol. 1992; 230: 329-334
        • Burstein N.L.
        The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye.
        Trans Ophthalmol Soc U K. 1985; 104: 402-409
        • Baudouin C.
        • Labbe A.
        • Liang H.
        • et al.
        Preservatives in eyedrops: the good, the bad and the ugly.
        Prog Retin Eye Res. 2010; 29: 312-334
        • Asbell P.A.
        Increasing importance of dry eye syndrome and the ideal artificial tear: consensus views from a roundtable discussion.
        Curr Med Res Opin. 2006; 22: 2149-2157